Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)


30 Sep 2019


Poster Display session 3


Bioethical Principles and GCP

Tumour Site

Non-Small Cell Lung Cancer


Nathalie Olympios


Annals of Oncology (2019) 30 (suppl_5): v671-v682. 10.1093/annonc/mdz263


N. Olympios1, M. Lacaud2, S. Cousse3, J. Dupont4

Author affiliations

  • 1 Laboratoire Ethique Médicale, Université Paris Descartes, 75006 - Paris/FR
  • 2 Oncologie Médicale, Centre Henri Becquerel, 76038 - ROUEN/FR
  • 3 Pneumology Department, Rouen University Hospital, 76000 - ROUEN/FR
  • 4 Assistance Publique Des Hôpitaux De Paris (aphp), Hospinnomics - Paris School of Economics, 75004 - Paris/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4118


Immune checkpoint inhibitors (ICI) have revolutionized treatment of advanced NSCLC. In France, concerns have been raised as to the financial burden of these therapies and fear that potential patients may be ruled out. The reality of budgetary restrictions implies for choices to be made considering both the quality of life these treatments procure as well as the financial burden they represent. From a physician’s point of view, due to financial constraints on public health facilities, physicians could restrain themselves from prescribing innovative expensive therapies.


This qualitative study questions the potential impact of drug prices on prescription choices made by thoracic oncologists. Ten French oncologists and two hospital pharmacists voluntarily underwent a semi-structured interview conducted by a student in an Ethics master’s degree. Interviews consisted of two distinct parts: one clinical case where treatment choices had to be made in the first-line and second-line advanced NSCLC setting and a second part consisting of open-ended questions.


Qualitative analysis of the interviews brings out that immunotherapy has radically changed the history of cancer treatment but that hopes in advanced NSCLC need to be tempered. Efficacy in a real-world setting is difficult to predict and efforts need to be made to identify accurate biomarkers. Financial matters are a source of discussions between fellow physicians and clinical pharmacists but not with patients. Physicians consider they have a duty to strictly respect guidelines particularly in a French universal healthcare system.


Rising costs of innovative drugs in oncology is a reality that forces a reconsideration of healthcare and drug regulation systems in order to be able to provide access to innovation for all eligible patients in the French universal healthcare system. Addressing this issue with physicians provides important insight on how treatment choices are made, their expertise and their involvement in this matter. Physicians are concerned about access to innovation for their patients and consider they ought to remain aware of these issues in order to participate in healthcare arbitration discussions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Laboratoire Ethique Médicale - Université Paris Descartes.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.